Abstract

Antibody Drug Conjugates: Highroad of New Technologies

Priyaranjan Pattanaik, Associate Research Director, Syngene International Limited

Antibody drug conjugates (ADC) are undergoing continuous make-over owing to a constantly changing technological landscape vis-a-vis our understanding of their safety and efficacy equation. New linkers, payloads and conjugation strategies pop up at a rapid pace which on one hand provide a wide range of options to choose from, while on the other it demands a thorough understanding of the complexity of these molecules in a physiological set up, before one can embark on pre-clinical and clinical development. In this context, this presentation will provide a summary of various ADC technologies and possible strategies for a smooth discovery and development roadmap.